Q2 surpassed expectations; now focus on deleveraging and operational delivery
14/08/26 -"The Q2 results exceeded consensus estimates, driven by a healthy showing from Crop Science, whereas the growth for the other two businesses was unexciting. The management maintained its full-year ..."
Pages
75
Language
English
Published on
14/08/26
You may also be interested by these reports :
14/08/26
The Q2 results exceeded consensus estimates, driven by a healthy showing from Crop Science, whereas the growth for the other two businesses was ...
14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...
13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...